thiotepa and Anemia, Aplastic studies

thiotepa and Anemia, Aplastic

thiotepa has been researched along with Anemia, Aplastic in 10 studies

Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Anemia, Aplastic: A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.

Research Excerpts

Excerpt	Relevance	Reference
"Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0."	9.08	Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995)
"Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0."	5.08	Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995)

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (70.00)	18.7374
1990's	1 (10.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (20.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

7 (70.00)

18.7374

1990's

1 (10.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

2 (20.00)

2.80

Authors

Authors	Studies
Kharya, G	4
Sapkota, S	3
Teotia, N	3
Chaudhary, M	3
Swathymon, KK	3
Chodan, P	3
Peters, S	3
Anthony, A	3
Sharma, B	4
Yadav, H	3
Bakane, A	4
Joseph, M	3
Jaiswal, SR	1
Bhat, S	1
Raj, R	1
Yadav, SP	1
Dua, V	1
Sen, S	1
Badiger, S	1
Uppuluri, R	1
Rastogi, N	1
Sachdev, M	1
Saifullah, A	1
Chakrabarti, S	1
PLAUCHU, M	2
DALMAIS, J	2
CHATAING, B	1
PHILIBERT, S	1
GUINGAND, M	1
BRIDGES, JB	1
BRIDGES, JM	1
EDELSTYN, GJ	1
LYONS, AR	1
Kennedy, MJ	1
Armstrong, DK	1
Huelskamp, AM	1
Ohly, K	1
Clarke, BV	1
Colvin, OM	1
Grochow, LB	1
Chen, TL	1
Davidson, NE	1
Navas, P	1
Grasset, D	1
Fickers, M	1
Speck, B	1
Bruce, D	1
Edgcomb, JH	1
Watkins, WE	1
Kozak, JA	1
Flanagan, MJ	1

Studies

Kharya, G

Sapkota, S

Teotia, N

Chaudhary, M

Swathymon, KK

Chodan, P

Peters, S

Anthony, A

Sharma, B

Yadav, H

Bakane, A

Joseph, M

Jaiswal, SR

Bhat, S

Raj, R

Yadav, SP

Dua, V

Sen, S

Badiger, S

Uppuluri, R

Rastogi, N

Sachdev, M

Saifullah, A

Chakrabarti, S

PLAUCHU, M

DALMAIS, J

CHATAING, B

PHILIBERT, S

GUINGAND, M

BRIDGES, JB

BRIDGES, JM

EDELSTYN, GJ

LYONS, AR

Kennedy, MJ

Armstrong, DK

Huelskamp, AM

Ohly, K

Clarke, BV

Colvin, OM

Grochow, LB

Chen, TL

Davidson, NE

Navas, P

Grasset, D

Fickers, M

Speck, B

Bruce, D

Edgcomb, JH

Watkins, WE

Kozak, JA

Flanagan, MJ

Trials

1 trial available for thiotepa and Anemia, Aplastic

Article	Year
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5 Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos	1995

Article

Year

Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5

Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos

1995

Other Studies

9 other studies available for thiotepa and Anemia, Aplastic

Article	Year
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2023
Impact of Conditioning Regimen and Graft-versus-Host Disease Prophylaxis on The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation for High-Risk Severe Aplastic Anemia in Children and Young Adults: A Report from the Pediatric Severe Apla Transplantation and cellular therapy, 2023, Volume: 29, Issue:3 Topics: Abatacept; Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Humans; Peripheral Bloo	2023
[3 cases of bone marrow aplasia, 1 of which is curable, due to triethylene thio-phosphoramide of RP 10, 090]. Lyon medical, 1962, Sep-23, Volume: 94 Topics: Anemia; Anemia, Aplastic; Bone Marrow; Humans; Pancytopenia; Phosphoramides; Thiotepa	1962
[MEDULLARY APLASIA DURING THE USE OF 4 ANTIMITOTICS: CARYOLYSIN, MYLERAN, THIOTEPA, ENDOXAN (APROPOS OF 32 CASES)]. Journal de medecine de Lyon, 1963, Dec-05, Volume: 44 Topics: Anemia; Anemia, Aplastic; Antimitotic Agents; Busulfan; Cyclophosphamide; Neoplasms; Nitrogen Mustar	1963
FEOTAL LIVER SUSPENSIONS IN THE TREATMENT OF MARROW APLASIA. British journal of cancer, 1965, Volume: 19 Topics: Anemia; Anemia, Aplastic; Antineoplastic Agents; Bone Marrow; Bone Marrow Diseases; Fetus; Hemoglobi	1965
[Fatal bone marrow aplasia due to endovesical thio-tepa]. Journal d'urologie et de nephrologie, 1973, Volume: 79, Issue:12 Pt 2 Topics: Age Factors; Aged; Anemia, Aplastic; Hematuria; Humans; Male; Mucous Membrane; Papilloma; Thiotepa;	1973
Thrombocythaemia. Familial occurrence and transition into blastic crisis. Acta haematologica, 1974, Volume: 51, Issue:5 Topics: Alkaline Phosphatase; Anemia, Aplastic; Blood Coagulation Tests; Bone Marrow Examination; Busulfan;	1974
Pancytopenia and generalized sepsis following treatment of cancer of the bladder with instillations of triethylene thiophosphoramide. The Journal of urology, 1967, Volume: 97, Issue:3 Topics: Aged; Anemia, Aplastic; Bone Marrow Examination; Carcinoma, Transitional Cell; Female; Humans; Infus	1967
Severe pancytopenia associated with the use of intravesical thio-TEPA. The Journal of urology, 1967, Volume: 98, Issue:4 Topics: Aged; Anemia, Aplastic; Carcinoma, Transitional Cell; Humans; Leukocyte Count; Male; Neoplasm Recurr	1967

Article

Year

Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.

Bone marrow transplantation, 2023, Volume: 58, Issue:2